Bristol Myers Squibb and Hengrui Pharma launch a multibillion-dollar collaboration spanning 13 oncology, hematology, and immunology programs to expand global drug development pipelines and accelerate early-stage clinical innovation.
Feliza Mirasol
Advertisement
Feliza Mirasol is the science editor for BioPharm International.
Articles by Feliza Mirasol
Approval of Biogen's high-dose Spinraza strengthens the company’s lifecycle strategy in SMA, enhancing durability while reinforcing competitive positioning in a rapidly evolving neurology market.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
President Trump Planning to Fire FDA Commissioner Marty Makary: Report
2
GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China
3
The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff
4
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
5